Viking Therapeutics (VKTX) Upgraded at BidaskClub

Viking Therapeutics (NASDAQ:VKTX) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.

A number of other brokerages also recently issued reports on VKTX. Maxim Group reissued a “buy” rating and issued a $8.00 price objective on shares of Viking Therapeutics in a research note on Friday, February 2nd. Roth Capital set a $6.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 29th. ValuEngine downgraded Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Viking Therapeutics in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Viking Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.00.

Viking Therapeutics (NASDAQ VKTX) traded up $0.53 during midday trading on Wednesday, hitting $6.49. The company’s stock had a trading volume of 691,532 shares, compared to its average volume of 1,370,000. Viking Therapeutics has a 1 year low of $0.88 and a 1 year high of $6.64. The company has a market cap of $232.63 and a price-to-earnings ratio of -7.64.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities analysts expect that Viking Therapeutics will post -0.86 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Sabby Management LLC acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at about $525,000. Sphera Funds Management LTD. acquired a new position in Viking Therapeutics during the 3rd quarter worth approximately $554,000. Citadel Advisors LLC acquired a new position in Viking Therapeutics during the 3rd quarter worth approximately $108,000. Creative Planning raised its stake in Viking Therapeutics by 600.0% during the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after buying an additional 60,000 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new position in Viking Therapeutics during the 2nd quarter worth approximately $124,000. 5.86% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/07/viking-therapeutics-vktx-upgraded-at-bidaskclub.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply